WO1998035658A2 - Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon - Google Patents
Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon Download PDFInfo
- Publication number
- WO1998035658A2 WO1998035658A2 PCT/EP1998/000743 EP9800743W WO9835658A2 WO 1998035658 A2 WO1998035658 A2 WO 1998035658A2 EP 9800743 W EP9800743 W EP 9800743W WO 9835658 A2 WO9835658 A2 WO 9835658A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- use according
- treatment
- diseases
- pulmonary surfactant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Definitions
- 2,3-Dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone is also known under the name coenzyme Q10.
- the substance plays a role in the respiratory chain and is also an antioxidant, which is able to intercept and render harmless radicals, which are passed on in particular by vitamins.
- Q-10 also determines the elasticity and dynamics of the cell membranes. It is therefore recommended as a single agent and in combination with other active ingredients for oral use.
- it is also offered in the form of a liposome cream, which allows the active ingredient to penetrate through the horny layer barriers and then accumulate in the different layers of the skin.
- the previously used liposome cream is produced on the basis of lecithins and forms a lipid bilayer around an aqueous interior.
- Q-10 accumulates within the membrane.
- it is suitable for the treatment of acne, psoriasis, neurodermatitis, burns, radiation damage, eczema, wounds, leg ulcers, skin cancer, skin aging, anus, periodontitis, ulcer, gastritis and rheumatism.
- it can be used in the form of powder in hard gelatin capsules or in an oily suspension in soft gelatin capsules. The applicant sells such a monopreparation with 30 mg of the active ingredient and, on medical request, with 120 mg of Q-10.
- the active ingredient can be used in the form of special liposome preparations.
- Liposomes are tiny spherical structures made up of layers of lipid and an aqueous interior. The layers are created by appropriately mixing the active ingredient with emulsifiers such as lecithin.
- Q-10 is stored directly in the lipid double membranes and makes them dynamic.
- a cream can also be used which additionally contains an effective amount of the pulmonary surfactant.
- liposomes based on the pulmonary surfactant only have one layer. These liposomes are able to penetrate the skin even more quickly and intensively. The combination of conventional liposomes and pulmonary surfactant surprisingly proved to be even more effective.
- the pulmonary surfactant is a complex of special phospholipids, neutral lipids and surfactant proteins that can be isolated from the lungs and which together form a single-layer barrier between the air and the liquid surface of the lungs.
- the pulmonary surfactant is formed in the alveolar type II cells and from there is released into the alveolar space.
- the pulmonary surfactant can also be recombined from the components.
- pulmonary surfactant has so far only been used for instillation in the case of diseases or deficiency symptoms in the lungs.
- Other applications have not previously been considered: it has now been found that pulmonary surfactant can unexpectedly penetrate into the outer skin and mucous membrane of the gastrointestinal, oral and vaginal areas, alone or in combination with liposomes.
- Pulmonary surfactant is therefore suitable for improving the effectiveness of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone and for accelerating the onset of action.
- physiologically pulmonary surfactant is released from the lung tissue, surprisingly, pulmonary surfactant can increase the tissue uptake of pulmonary surfactant and Q-10. This is particularly true for the further indications now found for the use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone in the treatment of diseases of the skin, mucous membranes and mucous membranes of the mouth , Stomach and intestines as well as the vagina.
- Q-10 alone and in combination with pulmonary surfactant in the treatment of tinnitus, incontinence, glycogenosis, cerebral palsy in children, arthritis, rheumatism, neurodermatitis, psoriaris and diabetic neuropathy are completely new.
- Q-10 in combination with Pulmonary Surfactant contributes to an improved treatment of diseases of the cardiovascular system, the muscles, the lungs, the nerves and the immune system.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT98908079T ATE251454T1 (de) | 1997-02-12 | 1998-02-11 | Verwendung von 2,3-dimethoxy-5-methyl-6- decaprenyl-1,4-benzochinon inder behandlung von tinnitus |
DE59809876T DE59809876D1 (de) | 1997-02-12 | 1998-02-11 | Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon inder behandlung von tinnitus |
EP98908079A EP1007018B1 (de) | 1997-02-12 | 1998-02-11 | Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon inder behandlung von tinnitus |
US09/355,932 US6228891B1 (en) | 1997-02-12 | 1998-02-11 | Use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19705232 | 1997-02-12 | ||
DE19705232.0 | 1997-02-12 | ||
CA002280253A CA2280253A1 (en) | 1997-02-12 | 1999-08-13 | Use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998035658A2 true WO1998035658A2 (de) | 1998-08-20 |
WO1998035658A3 WO1998035658A3 (de) | 1999-01-21 |
Family
ID=25681124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/000743 WO1998035658A2 (de) | 1997-02-12 | 1998-02-11 | Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon |
Country Status (4)
Country | Link |
---|---|
US (1) | US6228891B1 (de) |
EP (1) | EP1007018B1 (de) |
CA (1) | CA2280253A1 (de) |
WO (1) | WO1998035658A2 (de) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000047192A2 (de) * | 1999-02-11 | 2000-08-17 | Mse Pharmazeutika Gmbh | UBICHINON Qn ZUR BEHANDLUNG VON SCHMERZEN |
WO2000057871A2 (en) * | 1999-03-30 | 2000-10-05 | Purdue Research Foundation | Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof |
US6436449B2 (en) | 2000-03-02 | 2002-08-20 | Bo Gidlund | Use of a composition |
EP1281398A1 (de) * | 2000-05-09 | 2003-02-05 | Kaneka Corporation | Dermale zusammenstellungen die als wirkstoff coenzym q enthalten |
WO2003077951A1 (en) * | 2002-03-20 | 2003-09-25 | Kaneka Corporation | Percutaneous absorption promoters and compositions for treating athlete’s foot |
US6878514B1 (en) | 1999-03-30 | 2005-04-12 | Purdue Research Foundation | Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof |
WO2005034945A1 (fr) * | 2003-10-11 | 2005-04-21 | Thierry Schwitzguebel | Utilisation de la norphenazone et de coenzyme q pour le traitement de l'arthrose, l'arthrite et l'osteo-arthrite |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003026567A (ja) * | 2001-05-10 | 2003-01-29 | Kanegafuchi Chem Ind Co Ltd | 補酵素qを有効成分とする粘膜投与用組成物 |
CN100438862C (zh) * | 2001-05-10 | 2008-12-03 | 钟渊化学工业株式会社 | 辅酶q作为活性成分的经粘膜给药的组合物 |
US20030170223A1 (en) * | 2002-02-01 | 2003-09-11 | Board Of Trustees Of Michigan State University | Pulmonary vasodilator surfactant compositions and method of use |
AU2003218718A1 (en) * | 2002-03-09 | 2003-09-22 | Mse Pharmazeutika Gmbh | Utilization of ubiquinones for influencing the effect of histamine |
JP5247031B2 (ja) | 2004-01-22 | 2013-07-24 | ユニバーシティー・オブ・マイアミ | 局所用コエンザイムq10製剤 |
KR100891595B1 (ko) * | 2005-02-28 | 2009-04-03 | 주식회사 케이티앤지 | 혈액 단백질의 삼출을 감소시키는 조성물 |
AU2006219823A1 (en) * | 2005-03-02 | 2006-09-08 | Metanomics Gmbh | Process for the production of fine chemicals |
EP3607937A1 (de) | 2007-03-22 | 2020-02-12 | Berg LLC | Topische formulierungen mit erhöhter bioverfügbarkeit |
US20110046156A1 (en) * | 2008-03-05 | 2011-02-24 | Miller Guy M | Treatment of hearing and balance impairments with redox-active therapeutics |
US20110136231A1 (en) | 2008-04-11 | 2011-06-09 | Cytotech Labs, Llc | Methods and use of inducing apoptosis in cancer cells |
EP2430455A4 (de) | 2009-05-11 | 2013-09-04 | Berg Pharma Llc | Verfahren zur diagnose von stoffwechselerkrankungen mit epimetabolischen shiftern, mehrdimensionalen intrazellularen molekülen oder umgebungsbeeinflussern |
PE20130045A1 (es) * | 2010-03-12 | 2013-01-28 | Berg Pharma Llc | FORMULACIONES INTRAVENOSAS DE COENZIMA Q10 (CoQ10) Y METODOS DE USO DE LAS MISMAS |
AU2012240222B2 (en) | 2011-04-04 | 2017-04-27 | Berg Llc | Methods of treating central nervous system tumors |
CN103732214B (zh) | 2011-06-17 | 2017-04-12 | 博格有限责任公司 | 可吸入药物组合物 |
CN105338973A (zh) | 2013-04-08 | 2016-02-17 | 博格有限责任公司 | 使用辅酶q10联合疗法治疗癌症 |
SG11201601583TA (en) | 2013-09-04 | 2016-04-28 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2184355A (en) * | 1985-12-24 | 1987-06-24 | Seuref Ag | Ubiquinone pharmaceutical compositions |
US4824669A (en) * | 1985-04-11 | 1989-04-25 | Board Of Regents, The University Of Texas System | Formulations of coenzyme Q10 for intravenous use |
US5451569A (en) * | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1157269B (it) * | 1982-03-19 | 1987-02-11 | Seuref Ag | Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica |
JPS6336789A (ja) * | 1986-07-29 | 1988-02-17 | Mitsubishi Gas Chem Co Inc | 補酵素q↓1↓0の製造法 |
DE4410238A1 (de) * | 1994-03-25 | 1995-09-28 | Beiersdorf Ag | Hautpflegemittel |
-
1998
- 1998-02-11 WO PCT/EP1998/000743 patent/WO1998035658A2/de active IP Right Grant
- 1998-02-11 US US09/355,932 patent/US6228891B1/en not_active Expired - Fee Related
- 1998-02-11 EP EP98908079A patent/EP1007018B1/de not_active Expired - Lifetime
-
1999
- 1999-08-13 CA CA002280253A patent/CA2280253A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4824669A (en) * | 1985-04-11 | 1989-04-25 | Board Of Regents, The University Of Texas System | Formulations of coenzyme Q10 for intravenous use |
GB2184355A (en) * | 1985-12-24 | 1987-06-24 | Seuref Ag | Ubiquinone pharmaceutical compositions |
US5451569A (en) * | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
Non-Patent Citations (2)
Title |
---|
JAMES E F REYNOLDS: "MARTINDALE The Extra Pharmacopoeia Thirty-first Edition" 1996 , ROYAL PHARMACEUTICAL SOCIETY , LONDON, GB XP002078664 Page 1764: Ubidecarenone * |
PATENT ABSTRACTS OF JAPAN vol. 012, no. 248 (C-511), 13.Juli 1988 & JP 63 036789 A (MITSUBISHI GAS CHEM CO INC), 17.Februar 1988, * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000047192A2 (de) * | 1999-02-11 | 2000-08-17 | Mse Pharmazeutika Gmbh | UBICHINON Qn ZUR BEHANDLUNG VON SCHMERZEN |
WO2000047192A3 (de) * | 1999-02-11 | 2001-04-12 | Mse Pharmazeutika Gmbh | UBICHINON Qn ZUR BEHANDLUNG VON SCHMERZEN |
WO2000057871A2 (en) * | 1999-03-30 | 2000-10-05 | Purdue Research Foundation | Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof |
WO2000057871A3 (en) * | 1999-03-30 | 2002-01-31 | Purdue Research Foundation | Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof |
US6878514B1 (en) | 1999-03-30 | 2005-04-12 | Purdue Research Foundation | Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof |
US6436449B2 (en) | 2000-03-02 | 2002-08-20 | Bo Gidlund | Use of a composition |
EP1281398A1 (de) * | 2000-05-09 | 2003-02-05 | Kaneka Corporation | Dermale zusammenstellungen die als wirkstoff coenzym q enthalten |
EP1281398A4 (de) * | 2000-05-09 | 2006-04-05 | Kaneka Corp | Dermale zusammenstellungen die als wirkstoff coenzym q enthalten |
WO2003077951A1 (en) * | 2002-03-20 | 2003-09-25 | Kaneka Corporation | Percutaneous absorption promoters and compositions for treating athlete’s foot |
WO2005034945A1 (fr) * | 2003-10-11 | 2005-04-21 | Thierry Schwitzguebel | Utilisation de la norphenazone et de coenzyme q pour le traitement de l'arthrose, l'arthrite et l'osteo-arthrite |
Also Published As
Publication number | Publication date |
---|---|
US6228891B1 (en) | 2001-05-08 |
CA2280253A1 (en) | 2001-02-13 |
EP1007018A2 (de) | 2000-06-14 |
WO1998035658A3 (de) | 1999-01-21 |
EP1007018B1 (de) | 2003-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998035658A2 (de) | Verwendung von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon | |
EP1282446B1 (de) | Pharmazeutische und/oder kosmetische zubereitung enthaltend ein organosiloxan und ein phospholipid | |
DE102008034944B4 (de) | Mikroemulsion | |
DE60018881T2 (de) | Extrakte von mutterkraut (tanacetum parthenium) gegen entzündliche erkrankungen | |
RU2418575C2 (ru) | Нанолипосома с применением этерифицированного лецитина и способ получения таковой, а также композиция для профилактики или лечения кожных заболеваний, включающая таковые | |
EP0582239B1 (de) | Pharmazeutische und/oder kosmetische Zubereitung | |
EP1007021B1 (de) | Transdermale, orale und intravenöse zubereitungen von 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon | |
EP0037488B1 (de) | Pharmazeutisches Mittel zur Heilung von entzündlichen und/oder degenerativen und/oder atrophischen Schleimhauterkrankungen | |
AT505086A1 (de) | Pharmazeutisches mittel gegen juckreiz und juckreizbedingten schmerz | |
DE10349979A1 (de) | Medikamentöse gezielte lokale Lipolyse | |
EP0613685A1 (de) | Liposomen, enthaltend Chlorhexidindiacetat oder Chlorhexidingluconat | |
EP0198172B1 (de) | Pharmazeutische Zubereitung | |
US20040228910A1 (en) | Transdermal, oral and intravenous formulations of 2, 3-dimethoxy-5-methyl-6-decaprenyl-1, 4-benzoquinone | |
DE69927260T2 (de) | Topische pharmazeutische zusammensetzung zur behandlung von haut- oder zirkulatorischen krankheiten auf inflammatorischer, immun-, proliferativer oder degenerativer basis | |
EP0514435A1 (de) | Alkohol enthaltende wässrige gelartige phospholipidzusammensetzung, ihre verwendung und topische zubereitungen, die diese enthalten. | |
EP1398026B1 (de) | Verwendung von 2,3-Dimethoxy-5-methyl-6-decaprenyl-1,4-benzochinon in der Behandlung von Inkontinenz | |
EP2061432B9 (de) | Nano-vehikel für den transkutanen transport, diese enthaltende zubereitungen und deren anwendung | |
DE4403989B4 (de) | Pharmazeutische und/oder kosmetische Zusammensetzung sowie die Verwendung einer derartigen Zusammensetzung | |
KR100552923B1 (ko) | 퀘르세틴을 함유하는 두발조성물 | |
DE60319131T2 (de) | Dicolfenac-haltige liposomale schmerzstillende formulierung und ihre verwendung zur behandlung von pferden | |
EP1007022B1 (de) | Zubereitung des pulmonary surfactant zur instillation und zur oralen anwendung | |
DE4323174C2 (de) | Pharmazeutische und/oder kosmetische Zubereitung | |
US10117828B1 (en) | Anti-aging moisturizing emulsion | |
EP1131101A1 (de) | Khellin-zubereitung und deren verwendung zur topischen therapie | |
DE19608137A1 (de) | Lipid-Zubereitungen für diätetische Zwecke |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998908079 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09355932 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998535328 Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1998908079 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998908079 Country of ref document: EP |